Regulatory Path Retatrutide is not yet approved for the treatment of obesity or type 2 diabetes
Additional Potential Benefits Beyond sleep and stress, DSIP may provide other systemic advantages: Pain management: Preliminary studies suggest DSIP could influence pain pathways, potentially lowering pain perception
Abstract The European Medicines Agency (EMA) and the U.S
[1] [3] Understanding these multisystem effects is essential when evaluating potential adverse effects, including fatigue, as the widespread distribution of GLP-1 receptors means these medications influence numerous physiological processes beyond glucose metabolism
Pro tip: Retatrutide uses monthly dose escalation in trials
As of 2024, over 2% of Americans use GLP-1s for overweight/obesity, and around 4% use them overall (for any indication), with nearly half of users using them for weight loss